|Other Names||Kallikrein-10, 3421-, Normal epithelial cell-specific 1, Protease serine-like 1, KLK10, NES1, PRSSL1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6329d was selected from the N-term region of human KLK10. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Has a tumor-suppressor role for NES1 in breast and prostate cancer.|
|Tissue Location||Expressed in breast, ovary and prostate.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. The gene for KLK10 is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Its encoded protein is secreted and may play a role in suppression of tumorigenesis in breast and prostate cancers.
Diamandis, E.P., et al., Clin. Biochem. 37(3):230-237 (2004).Sauter, E.R., et al., Int. J. Cancer 108(4):588-591 (2004).Petraki, C.D., et al., Prostate Cancer Prostatic Dis. 6(3):223-227 (2003).Luo, L.Y., et al., Br. J. Cancer 86(11):1790-1796 (2002).Bharaj, B.B., et al., Prostate 51(1):35-41 (2002).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.